Company Active LTD

Company profile

Drishti Discoveries LTD.

Drishti Discoveries

Drishti Discoveries LTD. is a UK company with status active founded in 2019 based in East of England.

CRN
11998344
Founded
2019
Age
7

Overview

Legal name
DRISHTI DISCOVERIES LTD.
Region
East of England
Registered address
SALISBURY HOUSE
STATION ROAD
CAMBRIDGE
UNITED KINGDOM
CB1 2LA
Insolvency history
No

Latest accounts

Financial period: 1 Apr 2024 to 31 Mar 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
4

Company events

Reference milestones and recent Companies House filing stream events.

6 events
27 May
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

13 May
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

30 Sep
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNzc3Mjg2OGFkaXF6a2N4

Published 30 Sep 2024 03:10

15 May
2019

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2022
Funded years
2022, 2023
Age at first award
3 years

Projects

2023 Collaborative R&D Lead participant

Development of a Novel Gene Therapy for Neurodegenerative Diseases

1 Oct 2023 to 31 Dec 2024

Awarded
£210,936
Total cost £301,337

Amyotrophic Lateral Sclerosis (ALS) is a fatal motor neuron disease that causes death in patients within 3-5 years of diagnosis. Riluzole is the only approved drug in the UK that extends survival by 6 months. Increasing research in the pathophysiology of ALS has led to a deeper understanding of molecular mechanisms underlying the disease progression. Rece...

2022 Collaborative R&D Lead participant

Multitarget gene therapy for Neurodegenerative Diseases

1 Dec 2022 to 29 Feb 2024

Awarded
£196,475
Total cost £280,678

Amyotrophic Lateral Sclerosis (ALS) is a fatal motor neuron disease that causes death in patients within 3-5 years of diagnosis. Riluzole is the only approved drug in the UK that extends survival by 6 months. Increasing research in the pathophysiology of ALS has led to a deeper understanding of molecular mechanisms underlying the disease progression. Rece...

2022 Grant for R&D Lead participant

In-vivo gene therapy for Retinitis Pigmentosa

1 Nov 2022 to 30 Apr 2023

Awarded
£50,000
Total cost £50,000

Retinitis Pigmentosa (RP) is one of the leading causes of blindness worldwide. RP is a highly heterogeneous disease caused by mutations in one of over 60 genes. Due to the genetic nature of the disease, in-vivo gene therapy is considered to be the most promising approach to treating RP. However, the challenge of developing gene therapies for RP is that ma...

Product types

Collaborative R&D Grant for R&D